脂肪因子在肝硬化发病机制中的作用

魏思忱; 郑国启

脂肪因子在肝硬化发病机制中的作用

沧州市中心医院消化内科

详细信息

中图分类号: R575.2
计量
- 文章访问数: 3496
- HTML全文浏览量: 18
- PDF下载量: 746
- 被引次数: 0
出版历程
- 出版日期: 2012-01-20

Role of adipokine in the pathogenesis of cirrhosis of the liver

摘要

摘要: 脂肪组织不再只是一个储存过剩能量的惰性组织,同时也是一个活跃的内分泌器官。脂肪组织作为旺盛的内分泌器官已得到广泛认可,其分泌的大量脂肪因子如瘦素、细胞因子等参与维持机体能量稳态和调控糖、脂代谢平衡,对全身器官系统有重要的调节功能。研究发现脂肪因子影响肝脏的炎症、纤维化和细胞死亡。本文就各种脂肪因子与肝硬化的关系作一综述。
- 肝硬化 /
- 脂肪因子类
Abstract: Adipose tissue not only can store excess energy, but also can be an active endocrine organ.It was widely recognized that adipose tissue is a vigorous endocrine organ.Many of adipokines secreted by adipose tissue, such as leptin, cytokines, can participate in keeping energy balance, regulating metabolism balance of sugar and fat.They also have many important regulatory effect on the organs and systems of the whole body.Studies found that adipokines can influence inflammation, fibrosis and cell apoptosis of the liver.We summarize the relationship of adipokines and cirrhosis of the liver.
- liver cirrhosis /
- adipokines

HTML全文

参考文献(24)

[1] Peelman F, Waelput W, Iserentant H et al. Leptin: linking adipocyte metabolism with cardiovascular and autoimmune disease[J]. Prog Lipid Res, 2004, 43 (4) : 283-301.

[2]Singh A, Wirtz M, Parker N, etal.Leptin-mediated chan-ges in hepatic mitochondrial metabolism, structure, and pro-tein levels[J].Proc NatlAcad SciUSA, 2009, 106 (31) :13100-13105.

[3]Niu LW, Cao Q, Li J, et al.JAK/STAT pathway mediates leptin-induced Ⅰ collagen mRNA expression in human stel-late cells[J].Chin Pharmacool Bull, 2007, 23 (10) :1280-1285.

[4]Marra F.Leptin and liver tissue repair:do rodent models pro-vide the answers?[J].J Hepatol, 2007, 46 (1) :12-18.

[5]Wang J, Leclercq I, Brymora JM.Kupffer cells mediate lep-tin-induced liver fibrosis[J].Gastroenterology, 2009, 137 (2) :713-723.

[6]Bolukbas FF, Bolukbas C, Horoz M, et al.Ghild-Pugh clas-sification dependent alterations in serum leptin levels among cirrhotic patients:a case controlled study[J].BMC Gastro-enterol, 2004, 4 (1) :23-26.

[7] Piche T, Vandenbos F, Abakar-Mmahamat A, et al. The severity of liver fiberosis is associated high leptin levels in chronic hepatitis C[J]. Viral Hepat, 2004, 11 (11) : 91-96.

[8]Hyogo H, Tazuma S, Arihiro K, et al.Efficacy of atorvasta-tion for the treatment of nonalcoholic steatohepatitis with dyslipideia[J].Metabolism, 2008, 57 (12) :1711-1718.

[9]Ding X, Saxena NK, Lin S, et al.The roles of leptin and adi-ponectin:a novel paradigm in adipocytokine regulation of liver fibrosis and stellate cell biology[J].Am J Pathol, 2005, 166 (6) :1655-1669.

[10]Caligiuri A, Bertolani C, Guerra CT, et al.Adenosine mono-phosphate-activated protein kinase modulates the activated phenotype of hepatic stellate cells[J].Hepatology, 2008, 47 (2) :668-676.

[11]Weber TE, Kerr BJ, Spurlock ME.Regulation of hepatic per-oxisome prolierator-activated receptor alpha expression but not adiponectin by dietary protein in finishing pigs[J].J Anim Physiol Anim Nutr (Berl) , 2008, 92 (5) :569-577.

[12] Szalowska E, Elferink MG, Hoek A, et al. Resistin is more abundant in liver than adipose tissue and is not up-regulated by lipopolysaccharide[J]. J Clin Endocrinol Metab, 2009, 94 (8) : 3051-3057.

[13]Bertolani C, SanchoBru P, Failli P, et al.Resistin as an intra-hepatic cyctokine:overexpression during chronic injury and induction of proinflammatory actions in hepatic stellate cells[J].Am J Pathol, 2006, 169 (6) :2042-2053.

[14]Kakizaki S, Sohara N, Yamazaki Y, et al.Elevated plasma re-sistin concentrations in patients with liver cirrhosis[J].J Gastroenterol Hepatol, 2008, 23 (1) :73-77.

[15]Tiftikci A, Atug O, Yilmaz Y, et al.Serum levels of adipo-kines in patients with chronic HCV infection:relationship with steatosis and fibrosis[J].Arch Med Res, 2009, 40 (4) :294-298.

[16]Fu Y, Luo L, Luo N, et al.Proinflammatory cytokine produc-tion and insulin sensitivity regulated by overexpression of re-sistin in 3T3-L1 adipocytes[J].Nutr Metab, 2006, (3) :28-37.

[17] Bertolani C, Marra F. The role of adipokines in liver fibrosis[J]. Pathophysiology, 2008, 15 (2) : 91-101.

[18] Jarrar MH, Baranova A, Collantes R, et al, Adipokines and cytokines in non-alcoholic fatty liver disease[J]. Aliment Pharmacol Ther, 2008, 27 (5) : 412-421.

[19]Moschenl AR, Molnar C, Enrich B, et al.The novel adipokin Visfatin is involved in the pathogenesis of NAFLD[J].J Hep-atol, 2006, 44 (2) :S258.

[20] Aller R, de Luis DA, Izaola O, et al. Influence of visfatin on histopathologieal changes of noalcoholic fatty liver disease[J]. Dig Dis Sci, 2009, 54 (8) : 1772-1777.

[21] Moschen AR, Gerner R, Schroll A, et al. A key role for Pre-B cell colony-enhancing factor in experimental hepatitis[J]. Hepatology, 2011, 54 (2) :675-686.

[22]Huang JF, Huang CF, Yu ML, et al.Serum visfatin is correla-ted with disease severity and metabolic syndrome in chronic hepatitis Cinfection[J].J Gastroenterol Hepatol, 2011, 26 (3) :530-535.

[23]de Boer JF, Bahr MJ, Boker KH, et al.Plasma levels of PBEF/Nampt/visfatin are decreased in patients with liver cir-rhosis[J].Am J Physiol Gastrointest Liver Physiol, 2009, 296 (2) :G196-201.

[24] Ataseven H, Bahcecioglu IH, Kuzu N, et al. The levels of ghrelin, leptin, TNF-alpha, and IL-6 in liver cirrhosis and hepatocellular carcinoma due to HBV and HDV infection[J]. Mediators Inflamm, 2006, 2006 (4) : 78380.

施引文献

资源附件(0)

访问统计